FOR RESEARCH USE ONLY
Constituent evidence onlySkin research

KLOW

Multi-peptide blend (GHK-Cu / Larazotide / Orexin-A / KPV) researched for skin, gut and regenerative protocols.

01Intestinal barrier02Inflammatory signalling03Multi-pathway research
Molecular signature / klow
Structural identity

Multi-compound preparation spanning immune, barrier, neuroendocrine and copper pathways

Also known as

KPV / Larazotide / Orexin-A / GHK-Cu · Four-compound research blend

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

KLOW is a research-grade compounded blend combining four complementary peptides — KPV (anti-inflammatory tripeptide), Larazotide (tight-junction modulator), Orexin-A (wakefulness and metabolic regulator) and GHK-Cu (regenerative copper tripeptide). Designed as a single-injection regenerative stack, it is studied primarily for gut-barrier integrity, systemic inflammation and skin/connective remodelling.

The research question

KLOW combines compounds with markedly different biological targets. A sound research record should therefore report the amount of each constituent, not only total vial mass, and avoid treating unrelated mechanisms as proof of synergy.

Section 02

Mechanism & research themes

GHK-Cu drives collagen synthesis and broad transcriptomic remodelling. Larazotide antagonises zonulin to tighten intestinal tight junctions. KPV provides α-MSH–derived anti-inflammatory activity via NF-κB suppression. Orexin-A modulates wakefulness, appetite and energy expenditure via OX1R/OX2R receptors.

01

Combined gut-barrier, anti-inflammatory and regenerative activity

02

Single-injection convenience for stacked protocols

03

Skin and connective remodelling via the GHK-Cu component

04

Tight-junction support relevant to leaky-gut research models

05

Anti-inflammatory effect across NF-κB and α-MSH pathways

06

Daytime energy and appetite modulation via Orexin-A

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Constituent evidence only

Each constituent has a separate evidence base and exposure profile. There is no robust controlled evidence for this four-compound preparation as a single intervention.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 200–500mcg of the blend subcutaneously once daily, typically morning administration due to the orexin component. Cycles run 4–8 weeks.

Reported persistence

Variable across constituents — GHK-Cu approximately 1 hour, KPV short, Larazotide local GI activity, Orexin-A approximately 30–60 minutes plasma.

Calculator starting point

0.3 mg per reference dose

5 doses per week · 6-week cycle

3 mL default reconstitution volume

Recovery blend; commonly 4–6 weeks at 5×/week.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate KLOW
Section 05

Laboratory handling

Reconstitution reference

Reconstitute an 80mg vial with 4–5mL bacteriostatic water for approximately 16–20mg/mL working concentration. Swirl gently; the solution may appear faintly tinted due to the copper component.

Storage reference

Lyophilised: 2–8°C, stable 12–18 months. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Avoid evening administration — orexin component is wakefulness-promoting.

L2

Compounded blends lack standalone clinical trial data; outcomes are extrapolated from constituents.

L3

Avoid in copper-metabolism disorders (Wilson's disease) due to the GHK-Cu component.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only